SCHEMBL18706141

SCHEMBL18706141

O=C(c1ccc2c(Cl)c3c(nc2c1)CCCC3)N1CCN(C(=O)O)C2(CC2)C1

nearest known ligand 0.66

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.65
KMT2A Q03164 2/20 0.63
SMN1; SMN2 Q16637 2/20 0.62
ALDH1A1 P00352 1/20 0.61
HTT P42858 1/20 0.61
SMYD3 Q9H7B4 5/20 0.61
TP53 P04637 3/20 0.60
LMNA P02545 2/20 0.60
MEN1 O00255 1/20 0.60
POLB P06746 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18705832 0.93 MAPT (0.62) MAPTKMT2ASMN1; SMN2ALDH1A1HTT
SCHEMBL20768762 0.87 SMYD3 (0.62) MAPTKMT2ASMN1; SMN2ALDH1A1HTT
SCHEMBL18705780 0.85 SMYD3 (0.77) MAPTKMT2ASMN1; SMN2ALDH1A1HTT
SCHEMBL18706162 0.85 MAPT (0.79) MAPTKMT2ASMN1; SMN2ALDH1A1HTT
SCHEMBL20768864 0.83 SMYD3 (0.59) MAPTKMT2ASMN1; SMN2ALDH1A1HTT
SCHEMBL18705822 0.82 SMYD3 (0.77) KMT2AALDH1A1HTTSMYD3
SCHEMBL2216711 0.81 LMNA (0.80) MAPTKMT2ASMN1; SMN2ALDH1A1HTT
SCHEMBL2228000 0.81 LMNA (0.80) MAPTKMT2ASMN1; SMN2ALDH1A1HTT
SCHEMBL20768826 0.79 SMYD3 (0.63) MAPTKMT2ASMN1; SMN2ALDH1A1HTT
SCHEMBL18706199 0.78 ALDH1A1 (0.65) MAPTKMT2ASMN1; SMN2ALDH1A1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3371151-A1 COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS Agency For Science, Technology And Research (SG) 2018-09-12 EP disclosed
WO-2017061957-A1 COMPOUNDS FOR TREATMENT OF CANCER AND EPIGENETICS AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2017-04-13 WO disclosed